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Abstract 
Base excision repair (BER) repairs mutagenic or genotoxic DNA base lesions, thought to be 
important for both the etiology and treatment of cancer. Cancer phenotypic stress induces 
oxidative lesions, and deamination products are responsible for one of the most prevalent 
mutational signatures in cancer. Chemotherapeutic agents induce genotoxic DNA base 
damage that are substrates for BER, while synthetic lethal approaches targeting BER-related 
factors are making their way into the clinic. Thus, there are three strategies by which BER is 
envisioned to be relevant in cancer chemotherapy: (i) to maintain cellular growth in the 
presence of endogenous DNA damage in stressed cancer cells, (ii) to maintain viability after 
exogenous DNA damage is introduced by therapeutic intervention, or (iii) to confer synthetic 
lethality in cancer cells that have lost one or more additional DNA repair pathways. Here, we 
discuss the potential treatment strategies, and briefly summarize the progress that has been 
made in developing inhibitors to core BER-proteins and related factors. 
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Abbreviations 
5-FU, 5-fluorouracil; 5-FdU, 5-Fluoro-2’-deoxyuridine; 8-oxoG, 8-oxoguanine; 8-oxodG, 7,8-
dihydro-8-oxo-2´-deoxyguanosine; ADME, absorption, distribution, metabolism, and 
excretion; APE1, apurinic/apyrimidinic endodeoxyribonuclease 1; BCNU, 1,3-bis(2-
chloroethyl)-l-nitrosourea (BCNU); BER, Base excision repair; BRCA1/2, BRCA1/2 DNA 
repair associated; FaPyG, 2,6-diamino-4-hydroxy-5-formamidopyrimidine;  FEN1, flap 
structure-specific endonuclease 1; Gh, 5-guanidinohydantoin; LIG, DNA ligase; MBD4, 
methyl-CpG binding domain 4, DNA glycosylase; MEF, mouse embryonic fibroblast; MMC, 
mitomycin C; MPG, N-methylpurine DNA glycosylase; MTH1, MutT homolog 1; MUTYH, 
mutY DNA glycosylase; NEIL, nei-like DNA glycosylase; NTHL1, nth like DNA glycosylase 1;  
OGG1, 8-oxoguanine-DNA glycosylase 1; PARP1, poly(ADP-ribosyl) polymerase 1; POL, 
DNA polymerase; ROS, reactive oxygen species; SMUG1, single-strand selective 
monofunctional uracil-DNA glycosylase 1; Sp, spiroiminodihydantoin;  TDG, thymine-DNA 
glycosylase; TMZ, temozolomide; UNG, uracil-DNA glycosylase; XRCC1, X-ray repair cross 
complementing 1. 
  
1. Introduction 
Damage to nucleobases and backbone of DNA is one of the root causes of mutations, which 
enables tumors to acquire the hallmarks of cancer [1]. The quantitatively dominant repair 
pathway for these kinds of lesions is the base excision repair pathway (BER) [2–5]. 
Aggressive cancer cells contain higher levels of lesions such as uracil [6] or 8-oxoguanine (8-
oxoG) [5,7], and may therefore be expected to specifically rely on efficient repair pathways to 
maintain viability. Moreover, many (if not most) classical chemotherapeutic treatments exert 
their anti-cancer effect through damage to DNA [8,9]. Irradiation [10–15], fluoropyrimidines 
[16–18], antifolates [19–21], platinum drugs [22–28], demethylating agents [29], 
anthracyclines and monofunctional alkylating agents such as temozolomide [30–32] have 
been shown to directly or indirectly cause the DNA damage that is typically repaired by BER. 
Despite progress in immuno- and targeted therapies, these classical cancer treatment agents 
are likely to also be extensively used in the future. Therefore, the cellular pathways that 
protect against these lesions are promising targets for cancer adjuvant therapy. 
2. Base excision repair 
To cope with the large number of small base lesions that arise in the genome, human cells 
are equipped with DNA repair mechanisms which recognize and repair aberrant DNA 
structures. BER is the main pathway for the repair of small base lesions and is arguably the 
quantitatively most important DNA repair pathway in mammalian cells [8]. Given the 
importance of DNA damage in the evolution of cancer cells and the induction of BER 
substrates by cancer chemotherapy agents, there is a tremendous potential for targeting 
BER pharmaceutically. To this end at least three different treatment strategies may be 
envisioned (Figure 1).  
 
[FIGURE1 is a 2-column figure] 
Figure 1: Three therapeutic strategies for BER inhibitors. I. Sensitization to endogenous cancer-specific 
stress. Cancer cells harbor high levels of genomic instability in the form of ROS or APOBEC-induced lesions. By 
targeting the dominant repair pathway with BER inhibitors, it should be possible to increase the DNA damage 
level beyond what a replicating cell can handle. Normal cells do not have cancer-specific genomic instability and 
may cope with somewhat higher levels of damage of endogenous or environmental origin. II. Sensitization to 
chemotherapy or irradiation. BER inhibitors may potentiate the effect of chemotherapy or irradiation in both 
normal and cancer cells. Selectivity of current chemo- and radiotherapy regimens arises from targeting the high 
proliferation rate of cancer cells, but may also increase the DNA damage levels in normal cells causing dose- 
limiting toxicity. III. Synthetic lethality. Using BER inhibitors in cells deficient in compensatory repair pathways. 
leads to irreparable DNA damage and cell death. Normal cells are spared because they have lower levels of BER 
substrates in the first place and are proficient in the compensatory repair pathway.  
Briefly, BER is initiated by one of eleven known human DNA glycosylases that recognize and 
excise the aberrant base by cleaving the N-glycosidic bond between base and deoxyribose. 
AP endonuclease 1 (APE1) recognizes these abasic sites and incises the DNA backbone to 
generate a 3’ hydroxyl group. This structure is a substrate for DNA polymerases, which insert 
one or more nucleotides (short patch and long patch pathway, respectively). Following end-
SROLVKLQJE\IODSHQGRQXFOHDVHRUGHR[\ULERSKRVSKDWHO\DVHDFWLYLW\RI'1$SRO\PHUDVHȕ
DNA ligases reconstitute the integrity of the DNA backbone (Figure 2). For a detailed and 
comprehensive description of the mechanisms in BER and function of individual BER 
enzymes we recommend the following literature list to interested readers [2,33–39]. 
 
[FIGURE2 is a one-column figure] 
Figure 2: Simplified summary of potential strategic therapeutic targeting of the BER pathway: A) High 
levels of ROS in cancer cells can be complemented by Fenton reaction inducing nanoparticles, crosslinkers, 
radiotherapy and/or DNA intercalators; B) Recognition, binding and excision of nucleobase lesions can be 
targeted by, even covalently, inhibiting allosteric, metal-binding and active sites of DNA glycosylases, DNA-
protein interactions or by DNA intercalation; C) Bifunctional DNA glycosylases and APE1 can be unspecifically 
inhibited by reaction of nucleophiles with the AP site and specifically by inhibitors for allosteric, metal-binding and 
catalytic sites. Additionally downstream factors which release the modified BER enzymes from substrates might 
be targeted for reduced enzyme recycling; D) Inhibition of polymerases by traditional small molecules or DNA 
mimicking nucleotide analogues; E) Targeting of DNA substrate or DNA ligase enzymes can be performed by 
inhibitors or interaction with active, allosteric and metal-binding sites. 
 
In principle, the BER pathway may be drugged at any point of this process (Figure 1). 
However, knockout mice for the core enzymes of the pathway, i.e. Ape1, Polb, Xrcc1, Lig3 
and Fen1 are all embryonic lethal, with the exception of Parp1-/-, which appear to be viable 
and fertile. On the other hand, knockout mice for DNA glycosylases are all viable and fertile, 
with the exception of Tdg-/-. These observations indicate that inhibitors to the core enzymes 
may have unforeseen on-target toxicities in normal tissues, but inhibitors to DNA 
glycosylases and PARP1 may be tolerated. 
3. Known BER inhibitors 
The substrate specificity and reaction mechanism during BER repair may be exploited by 
using small molecules targeting the different intermediate stages of both long and short patch 
repair pathways (Figure 2).  
To this date, targeting the initial repair steps performed by the DNA glycosylases has 
resulted in only moderate success of developing small molecules against UNG, NEIL1 and 
OGG1 [40–46]. The underlying reasons for this might be due to the challenging nature of 
drugging carbohydrate or DNA-binding proteins, often regarded as close to undruggable, and 
glycosylases in DNA-bound and apo-states in general [47–49]. 
Only recently these obstacles have been overcome for OGG1 by the development of a 
potent first in class compound series by Tahara et al [50]. However, it remains to be seen 
how these unusual nonpolar molecules behave in different cell lines and ADME studies.  
Like APE1, some DNA glycosylases with bifunctional mode of action can be inhibited from 
binding the intermediate abasic site. Methoxyamine, which is already used in the clinic in 
combination therapies, or small molecules with similar nucleophilic properties are examples 
of this interesting approach of mimicking the active DNA glycosylase site [51–53]. 
Additionally, a number of other substances are reported in the literature [54–63]. 
'HYHORSPHQWRILQKLELWRUVDJDLQVW'1$3RO\PHUDVHȕKDVEHHQDWWHPSWHGLQDQXPEHURI
studies [64–68]. However, most of the identified small molecules either lack potency or 
specificity. Recently, a DNA mimicking compound was shown to increase cytotoxicity in 
combination therapy with methyl methanesulfonate in HeLa cells [69]. DNA Ligases can also 
be targeted by several mechanisms. Consequently, an impressive amount of work has been 
invested into different approaches, but only yielding inhibitors with moderate potency and 
specificity [70]. A benzocumarine-stilbene hybrid molecule was recently reported to reduce 
the growth of breast cancer in a mouse model and is the most advanced DNA ligase-inhibitor 
known so far [71]. 
The only approved drugs targeting the BER pathway are for the treatment of BRCA-mutated 
breast and high grade serious ovarian cancer. Olaparib, Niraparib and Rucaparib target 
PARP1 during single-strand break repair and in contrast to simple catalytic inhibition by 
covalent substances cause toxicity due to the formation of double-strand breaks. All three 
drugs are currently in clinical trials for combination therapies with classical DNA damaging 
agents [72–76]. 
4. BER as an anti-cancer target 
4.1 Sensitization to endogenous cancer-specific DNA damage 
The high mutation load in cancer cells is to a large degree driven by endogenous DNA 
damage caused by metabolic imbalances. Activation of oncogenes contributes to genomic 
instability through replication stress at an early step in carcinogenesis [77,78]. While the 
mechanistic details underlying the replication stress are far from clear, at least a subset of 
oncogenes such as c-Myc and Ras confer an increase in reactive oxygen species (ROS) and 
oxidative DNA damage [79–81], causing higher levels of oxidized bases in cancer cells 
[82,83]. While the absolute quantification of oxidized bases in the genome has proven to be 
technically challenging [84,85], oxidized bases in the genome of cancer cells or free oxidized 
bases and nucleotides in serum and urine are robust biomarkers for cancer [7,86], also 
reviewed in [5,34,87]. It is thought that a high load of ROS drives cancer cell proliferation and 
metastasis at the cost of causing oxidative damage to macromolecules [88]. 
The high level of ROS in cancer could in principle be handled in two ways: by quenching the 
pro-survival, growth stimulatory ROS signaling using antioxidants or by increasing the 
amount of ROS to allow its damaging effects to incapacitate cancerous cells. While pro-
oxidant conditions such as inflammation and exposure to ionizing radiation promote tumor 
development, agents that directly or indirectly increase intracellular ROS are used 
extensively and with great efficacy in cancer therapy [89]. On the other hand, while increased 
intake of foods rich in antioxidants are recommended to the general population for being 
protective against cancer, it has been shown that excessive antioxidant treatment stimulates, 
rather than inhibits, the generation and spread of cancer in mice [90,91] and humans [92,93]. 
Taken together, this suggests that high ROS in cancer cells with its associated inevitable 
damage to DNA and macromolecules forms a barrier to carcinogenesis and metastasis. 
Pathways for preventing the accumulation of oxidative DNA lesions may therefore raise the 
threshold of how much oxidative stress a replicating cell can handle. Thus, these pathways 
are promising targets for cancer therapy. The best evidence for this concept was recently 
provided by us and others, by establishing MTH1 inhibition as a strategy to sensitize cancer 
cells to endogenous stress [94–96].  
Guanine has the lowest redox potential among nucleobases and is therefore highly prone to 
oxidation [4,36,97], resulting in oxidation products 8-oxoG and 2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FaPyG) in DNA or in the deoxynucleotide pool (8-oxodGTP). 
Mammalian cells are equipped with three enzymes which act in concert to prevent the 
mutagenic potential of 8-oxoG: MutT homolog 1 (MTH1), MUTYH and OGG1 (Figure 3). 
MTH1 sanitizes the nucleotide pool from 8-oxodGTP, thereby preventing its incorporation 
into DNA, and MUTYH excises adenines misincorporated opposite genomic 8-oxoG. 
However, the main enzyme to remove genomic 8-oxoG is OGG1, which specifically 
recognizes and excises 8-oxoG paired with cytosine in double-stranded DNA. Deficiencies in 
this repair system may lead to increased mutagenesis or cell death through different 
mechanisms [98–100]. Moreover, 8-oxoG is prone to further oxidation, resulting in the 
generation of 5-guanidinohydantoin (Gh) or spiroiminodihydantoin (Sp), which in turn are 
substrates for the NEIL DNA glycosylases [36,101,101–104]. 
  
  
[FIGURE3 is a 1.5-column figure] 
Figure 3: Cellular defense mechanisms against oxidized guanines. Cancer cells contain high levels of 8-
oxodGTP, which may be incorporated into DNA unless hydrolyzed by MTH1. Once into DNA, 8-oxoguanine is 
recognized and repaired by OGG1, and downstream BER reconstitutes the original DNA sequence. However, 
replicative DNA polymerases may frequently insert adenine opposite 8-oxoguanine, causing an A:8-oxoG mispair. 
The adenine is a substrate for MUTYH, providing downstream BER the chance to insert a cytosine opposite 8-
oxoguanine, and generate a substrate for OGG1 to remove the offending 8-oxoguanine from DNA. When MTH1 
is inhibited or lowly expressed, inhibition of either OGG1 or MUTYH may be expected to be toxic to cancer cells, 
triggering toxic futile repair cycles and/or cell death. 
MTH1 facilitates cell survival and proliferation after oncogene-induced oxidative stress [105–
109], and inhibitors to MTH1 are promising candidates for anti-cancer therapy [94–96]. While 
the underlying biology behind MTH1’s involvement in tolerance to oncogene-induced 
oxidative stress is emerging [87,105–111], the biology of small molecule MTH1 inhibitors 
remains unresolved in the literature. Several MTH1 inhibitor series fail to kill cancer cells, 
despite apparent successful target engagement in cells [112–115]. A key observation is that 
the anti-cancer effect seems to be coupled to accumulation of oxidized bases in the genome, 
as the MTH1 inhibitors that fail to accumulate oxidized bases also fail to kill cancer cells 
[96,115]. Since these oxidized bases are substrates for BER, it follows that inhibitors to BER 
could be used to either potentiate the effect of MTH1 inhibitors, or to kill subsets of cancers 
where the cancer cell relies more on downstream BER than MTH1 to maintain viability. This 
implies that the downstream repair enzymes OGG1 and MUTYH may be promising 
candidates to inhibit proliferation of high ROS cancers, either alone or in combination with 
MTH1 inhibitors. Consistently, MUTYH knockdown reduces cell proliferation and tumor 
growth and increases apoptosis in pancreatic cancer cells [116]. In a T-cell ALL cell line, 
proliferation is inhibited and apoptosis is induced by knockdown of MTH1 and MUTYH, both 
alone and synergistically [100]. Furthermore, OGG1 overexpression protects against Ras-
induced senescence [117]. These observations point to a role of OGG1 and MUTYH in 
protecting against endogenous oxidative cancer-related stress, and suggest that these DNA 
glycosylases may be promising targets for the development of DNA glycosylase inhibitors.  
4.2 Sensitizing cells to cancer therapy-induced DNA damage 
Targeting the BER pathway is a promising strategy to sensitize cancer cells to chemo-and 
radiotherapy since many of the current therapies aim to induce genotoxic DNA lesions. 
These therapies are however not specific for cancer, but introduce genotoxic damage in all 
proliferating cells. Their efficacy is thus limited by the toxic side effects resulting from 
targeting the non-cancerous proliferating cells. Efficient sensitization to chemotherapy and 
radiotherapy has been observed in several biological systems where one or more BER 
enzymes were depleted. It is thought that BER inhibitors will recapitulate these phenotypes. 
Interestingly, in some instances overexpressing some BER components, rather than their 
depletion, conferred a higher sensitivity. This can be explained in light of their role in BER 
and the nature of DNA intermediates that arise when such BER components are 
manipulated. Examples of these effects are briefly summarized below and in Table 1. 
A number of inhibitors of the folate pathway results in the accumulation of dUMP in the 
nucleotide pool and misincorporation of uracil into DNA leading to thymine-less death [118–
120]. The resulting genomic U:A base pairs are predominantly recognized and excised by 
UNG in mammals [121–123]. Notably, UNG expression was found to positively correlate with 
pemetrexed resistance in human lung cancer cell lines and UNG depletion resulted in 
enhancing its cytotoxic effect [20,21]. Moreover, Bulgar and colleagues [19] were able to re-
sensitize UNG+/+ cells with acquired pemetrexed resistance by co-treating the cells with 
methoxyamine, highlighting the importance of BER in mediating the cellular response to 
pemetrexed treatment.  
BER is also implicated in the cytotoxicity of 5-fluorouracil (5-FU), a widely used anticancer 
drug whose metabolites are incorporated into both DNA and RNA in addition to inhibiting 
thymidylate synthase [124]. Of the five different repair pathways shown to process genomic 
5-FU, UNG is the main repair pathway in cancer cells, with only a modest contribution of 
SMUG1, TDG, MBD4 or mismatch repair in repairing 5-FU containing DNA [16]. Interestingly, 
knocking down uracil-DNA glycosylases or employing BER inhibitors did not significantly 
enhance the fluoropyrimidine cytotoxicity. Instead, 5-FU cytotoxicity under the conditions 
employed was found to be mainly due to its incorporation into RNA rather than the DNA-
mediated effects [16]. However, Yan et al. [18] pointed out that p53 status together with UNG 
plays a role in determining the cytotoxicity of 5-Fluoro-2’-deoxyuridine (5-FdU, floxuridine), 
another fluoropyrimidine that is efficiently incorporated into DNA rather than RNA. In absence 
of UNG, genomic 5-FU was found to block replication and induce double-strand breaks [125]. 
Consequently, targeting or depleting core BER factors such as XRCC1 and PARP1 
sensitizes cancer cells to 5-FdU [126–128]. This strongly suggests that BER is an important 
modulator of the DNA-mediated effects of 5-FU. 
 
Targeting BER also enhances the sensitivity to temozolomide (TMZ), a DNA alkylating agent 
used in the treatment of glioblastoma. Besides O6-methylguanine adducts, TMZ- induced 
DNA lesions include N3-methyladenine and N7-methylguanine base lesions, which are 
recognized by methyl purine DNA glycosylase (MPG) [32]. It is UHSRUWHGWKDWGHSOHWLQJ32/ȕ
sensitizes murine embryonic fibroblasts to TMZ. This sensitivity is further enhanced by 
overexpressing MPG, suggesting that the accumulation of BER intermediates is likely the 
cause behind such hypersensitivity [31]. Another study by Tang and colleagues [30] shows 
that MPG overexpression significantly enhances TMZ cytotoxicity when combined with 
methoxyamine. Such a potentiation effect is abolished by overexpressing 32/ȕKLJKOLJKWLQJ
that botK03*DQG32/ȕFRQWULEXWHWR70=HIILFDF\DQGLQIOXHQFHPHWKR[\DPLQH
potentiation of TMZ [30]. Interestingly, MPG depletion in murine cells is reported to confer 
increased sensitivity to two bifunctional alkylating agents; namely 1,3-bis(2-chloroethyl)-l-
nitrosourea (BCNU) and mitomycin C (MMC) suggesting that MPG initiated BER plays an 
important role in counteracting those agents [129]. 
The BER pathway also influences the cytotoxicity of DNA crosslinking agents such as 
psoralen and cisplatin. Psoralen- induced monoadducts function as substrates for NEIL1 
where HeLa cells deficient in NEIL1 and/or APE1 exhibit hypersensitivity to psoralen upon 
UVA photoactivation [130]. Furthermore, NEIL1 and NEIL3 have been shown to be involved 
in the repair of bulky psoralen- induced interstrand cross-links [131–133]. On the other hand, 
cisplatin cytotoxicity is attributed to inducing different types of DNA lesions including mono-
adducts, intrastrand and interstrand cross-links [134] in addition to resulting in an increased 
generation of ROS and oxidative DNA damage [28]. Importantly, UNG, POLȕ and APE1 
have been shown to be involved in modulating cisplatin resistance [135]. Indeed, depleting 
POLȕ81*RUXVLQJPHWKR[\DPLQHFRQIHUUHGcisplatin resistance in MDA-MB-231, HeLaS3, 
A2780 human cell lines and MEFs by affecting the processing of cisplatin DNA interstrand 
crosslinks [23]. APE1 expression level in tumor specimens from patients with non-small cell 
lung cancer was found to positively correlate with cisplatin resistance and high APE1 
expression was associated with poor prognosis. This was further supported by showing that 
APE1 depletion sensitises A549 cells to cisplatin [136]. NTHL1 is another BER glycosylase 
that can serve as a target to potentiate cisplatin cytotoxic effects. Knocking down NTH1 was 
found to re-sensitise the otherwise cisplatin resistant Y-box-binding protein-1 overexpressing 
tumor cells [22]. 
Finally, the BER status affects the cellular response to ionizing radiation. Irradiation results in 
a broad range of DNA lesions including single strand breaks, double strand breaks and 
oxidized DNA lesions. The latter are recognized and repaired by the BER pathway. 
Accordingly, a number of BER aberrations are reported to influence the response to 
radiotherapy and thus offer a potential strategy for radiosensitization [10]. For instance, the 
status of OGG1 activity in human leukemia cell lines is regarded as a key player in 
determining cell survival following irradiation [12]. In addition, NTHL1 overexpression 
sensitizes human lymphoblastoid cells to gamma-irradiation [137]. Furthermore, SMUG 
depletion in UNG deficient cells results in radiosensitization [138].  
 
4.3 Synthetic Lethality approaches 
The dependence on compensatory repair pathways in cancer cells may be exploited as a 
therapeutic strategy in cancer therapy. Cancer cells deficient in a certain repair pathway can 
be specifically targeted via the inhibition or down-regulation of a compensatory repair 
pathway. Normal cells are protected by the activity of the same repair pathways mutated in 
the tumor (Figure 1). A well described example of such synthetic lethality is provided by 
inhibition of PARP1 in cells deficient in homologous recombination [139,140]. While PARP1 
does not participate in BER per se [141–143], it is activated by the single-strand break 
intermediates. Three inhibitors, Olaparib, Niraparib and Rucaparib, are already approved for 
the treatment of hereditary breast and ovarian cancer and clinical trials of these compounds 
in combination therapies with DNA damaging agents are in progress [144,145]. However, the 
success of PARP1-inhibitors hides a very complex biology, where inhibition of catalytic 
activity can be well tolerated. Instead, compounds that trap PARP1 covalently at single-
strand break repair intermediates cause toxicity because these structures are converted into 
double-strand breaks in BRCA1/2-deficient cells, whereas poor PARP1-trappers do not 
cause toxicity [146,147]. Thus, the pre-clinical efficacy of PARP-inhibitors correlate well with 
their ability to trap PARP1, at least in a monotherapy setting [144,148]. Combination 
regimens, while highly efficient in vitro, are hard to administer clinically, because of dose-
limiting toxicity in normal tissues [144]. This stems from the lack of cancer selectivity of the 
classical chemotherapeutic drugs, which are toxic to all proliferating cells. 
Other recent examples of synthetic lethality involving BER proteins include the inhibition of 
APE1, which sensitizes cells deficient in DSB repair [149]. The combination of inhibitors of 
double-strand break repair [150] or PARP-1 [143] sensitize cells deficient in XRCC1. Cells 
lacking functional mismatch repair often display enhanced tolerance to cytotoxic drugs, but 
may be sensitized to methotrexate by downUHJXODWLRQRI32/ȕ or OGG1 [151].   
5. Summary and perspectives 
Not many high quality small molecule inhibitors of the BER pathway exist today, although the 
underlying role of BER in the repair of DNA damage and the success of the PARP1-inhibitors 
justify developing new compounds. Targeting the DNA glycosylases would be of special 
significance, since knockout mice for these enzymes are viable, fertile and for the most part 
healthy [152]. 
One issue that has stopped researchers from creating small molecule inhibitors of various 
BER factors is the concept of redundancy and “backup” repair pathways that are postulated 
to account for the absence of clear phenotypes following experimental treatments. Yet, truly 
redundant pathways are not favored through evolution, because inactivating mutations in 
“backup” genes would not be selected against. Even though BER enzymes have somewhat 
overlapping substrate specificities, they are all very well conserved in higher eukaryotes, 
indicating there is a selective pressure maintaining them and implying that all BER factors 
have separate, specialized functions. Although apparently inseparable in vitro or in a lysate, 
in cells these functions are separated in time during the cell cycle [153] or embryonal 
development [154], in space in subnuclear compartments such as telomeres, replication 
forks, eu- or heterochromatin, nucleolus or by binding to different interaction partners. Thus, 
if one BER factor is deficient or inhibited, repair by a suboptimal pathway will be triggered 
and the DNA damage will be repaired at a suboptimal time, place or by the wrong 
downstream repair factors. An example of this is that despite there being at least 5 different 
pathways that are biochemically capable of removing 5-FU from DNA [16], depletion of only 
one factor has proven sufficient to sensitize cells to fluoropyrimidines in various contexts 
[125,138,155]. Therefore, despite the presence of apparent redundancy, targeting of only a 
single BER protein may still be sufficient to achieve pharmaceutical efficacy. 
That being mentioned, the biology of the BER pathway is very complex. While the idea that 
proteins overexpressed in cancer are promising therapeutic targets is a common 
assumption, this may not hold true for the BER pathway since the intermediates of the BER 
pathway, AP-sites and strand breaks in various configurations, are themselves genotoxic 
[143,156–163]. Thus, overexpression of DNA glycosylases may sensitize rather than rescue 
cells from treatment with genotoxic agents [137,160,162,164–167], or cells deficient in the 
same DNA glycosylases may be resistant against genotoxic treatments [98,160,162,164]. 
Second, overexpression of BER proteins may interfere with other repair pathways. 
([SUHVVLRQRI'1$SRO\PHUDVHȕLVPXWDJHQLc since it interferes with high fidelity 
polymerases [168] and overexpression of proteins such as NTHL1 is sufficient to cause 
replication stress and genomic instability, even when a catalytically dead mutant is 
expressed [169]. This implies that the expression levels of BER proteins must be tightly 
regulated in order not to impede cancer cell proliferation, which is under a strong selective 
pressure to divide fast. 
Moreover, if potent and pharmacologically acceptable BER inhibitors are to be generated, we 
have so far only vague ideas on how to implement them in therapy since our understanding 
of DNA damage in cancer in general is lacking. While we know cancer is genomically 
unstable and BER substrates are prevalent in cancer genomes, we only have a rudimentary 
understanding of how the different lesions contribute to the cancer phenotype, and how this 
might be exploited to kill cancer cells. Likewise, a quantitative understanding is lacking. The 
levels of uracil and 8-oxoG in normal cells seem to be no more than 1 lesion per 10^6 bp 
[6,34,85,170], but the absolute level that can be tolerated by cancer and normal cells is 
unknown. This understanding would be vital to avoid damage to normal cells, especially in 
combination treatments, as seen for the PARP1-inhibitors [144]. Avoiding on-target toxicity in 
normal tissues would be of particular importance if the core enzymes of the pathway are 
targeted, where knockout mice are embryonic lethal.  
  
Table 1: Targeting the BER pathway to sensitize cancer cells to chemo- and radiotherapy induced DNA damage. 
DLD1 and HT29, colorectal adenocarcinoma cell lines; H460 and A549, non-small-cell lung cancer cell lines; 
OVCAR-8 and A2780, ovarian cancer cell lines; MEF, mouse embryonic fibroblasts; LN428; glioma cell line; Ab1, 
mouse embryonic stem cells; HeLa and HeLa S3, cervical adenocarcinoma cell lines; MCF7 and MDA-MB-231, 
breast cancer cell lines; TK6, human lymphoblastoid cells. 
Cell line BER manipulation or 
inhibition 
Chemo- or 
radiotherapy 
Treatment 
Outcome 
Reference 
 
DLD1  
 
 
UNG depletion 
 
 
 
 
Pemetrexed 
 
 
 
Sensitization 
 
[20] 
 
DLD1, 
H460 & A549 
Xenografts 
 
Methoxyamine treatment 
 
[19] 
 
 
OVCAR-8 
 
XRCC1 depletion 
 
 
 
 
 
 
 
 
Floxuridine 
 
 
 
 
 
 
 
Sensitization 
 
 
 
 
 
[126] 
 
PARP1 depletion 
 
 
PARP inhibition  
 
 
 
HT29 
 
 
XRCC1 depletion 
 
 
 
[128] 
 
APE1 depletion 
 
 
MEF 
 
 
POLȕGHSOHWLRQ 
 
 
 
Temozolomide 
 
 
 
Sensitization 
 
 
[31] 
 
LN428 
 
 
MPG overexpression with  
Methoxyamine co-treatment 
 
 
[30] 
 
Ab1 
 
MPG depletion 
 
Mitomycin C  
or BCNU 
 
Sensitization 
 
[129] 
 
 
HeLa 
 
 
NEIL1 depletion 
 
 
Psoralen 
 
 
Sensitization 
 
[130] 
 
APE1 depletion 
 
 
A549 
 
 
APE1 depletion 
 
 
 
 
 
Cisplatin 
 
 
Sensitization 
 
[136] 
 
MCF7 
 
NTHL1 depletion 
 
 
[22] 
 
MEF, A2780, 
HeLa S3, 
MDA-MB-231 
 
POLȕ depletion, 
UNG depletion,  
Methoxyamine treatment 
 
 
Resistance 
 
[23] 
 
TK6 
 
 
NTHL1 overexpression 
 
 
 
 
Ȗ-radiation 
 
 
 
Sensitization 
 
[137] 
 
MEF 
 
SMUG1 depletion in UNG -/- cells 
 
[171] 
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